Stock Analysis

Analysts Expect Breakeven For THC Biomed Intl Ltd. (CSE:THC) Before Long

With the business potentially at an important milestone, we thought we'd take a closer look at THC Biomed Intl Ltd.'s (CSE:THC) future prospects. THC Biomed Intl Ltd. produces and sells medical and recreational cannabis in Canada. The company’s loss has recently broadened since it announced a CA$162k loss in the full financial year, compared to the latest trailing-twelve-month loss of CA$4.6m, moving it further away from breakeven. The most pressing concern for investors is THC Biomed Intl's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for THC Biomed Intl

Expectations from some of the Canadian Pharmaceuticals analysts is that THC Biomed Intl is on the verge of breakeven. They anticipate the company to incur a final loss in 2021, before generating positive profits of CA$1.1b in 2022. Therefore, the company is expected to breakeven just over a year from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 166%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

earnings-per-share-growth
CNSX:THC Earnings Per Share Growth April 6th 2021

Given this is a high-level overview, we won’t go into details of THC Biomed Intl's upcoming projects, however, keep in mind that by and large pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 34% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of THC Biomed Intl which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at THC Biomed Intl, take a look at THC Biomed Intl's company page on Simply Wall St. We've also compiled a list of essential aspects you should look at:

  1. Valuation: What is THC Biomed Intl worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether THC Biomed Intl is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on THC Biomed Intl’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

When trading THC Biomed Intl or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Sponsored On Behalf of CiTech

Valuation is complex, but we're here to simplify it.

Discover if THC Biomed Intl might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020


Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

About CNSX:THC

THC Biomed Intl

Produces and sells medical and recreational cannabis in Canada.

Overvalued with worrying balance sheet.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
2 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
22 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

IM
HOH logo
Imthetxarbi on High Arctic Overseas Holdings ·

Deep Value Multi Bagger Opportunity

Fair Value:CA$471.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative